Every 8-K that Viemed Healthcare, Inc. (VMD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow VMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VMD filings page.
VIEMED HEALTHCARE, INC. (VMD) released an August 2026 investor presentation describing a rapidly growing, home-based clinical care platform in complex respiratory and related services, plus updated financial performance and 2026 guidance.
For 2025, net revenue was $270 million, up 21% year over year, with Adjusted EBITDA of $61.4 million (22.7% margin), free cash flow of $28.1 million, and net income attributable to VMD of $14.9 million. The company reports serving over 198,000 patients across all 50 states, with ventilation remaining the largest line but an expanded mix including sleep, oxygen, airway clearance, women’s health and staffing.
For 2Q 2026, revenue was $78.1 million (up 24% year over year), Adjusted EBITDA $13.7 million, and free cash flow $8.6 million, with no net debt and $10.7 million of cash plus $46 million of undrawn credit facilities. Management’s 2026 guidance calls for net revenue of $314–$320 million and Adjusted EBITDA of $64–$68 million, with net capex of 8.5%–10% of net revenue and continued share repurchases under a program authorizing up to 5% of shares outstanding.
Viemed Healthcare reported record second-quarter 2026 net revenue of $78.1 million, up 23.9% from a year earlier and 3.6% sequentially. Net income attributable to the company was $2.8 million, or $0.07 per diluted share, while Adjusted EBITDA was $13.7 million, a 4.0% year-over-year decrease. The company generated $15.9 million of operating cash flow and $8.6 million of free cash flow in the quarter.
Viemed ended June 30, 2026 with $10.7 million in cash, long-term debt of $6.4 million, working capital of $6.1 million, and $46 million available under existing credit facilities. The company reported a record 12,635 ventilator patients, plus strong growth in PAP therapy and sleep resupply patients, and repurchased 530,802 shares for $5.1 million. Full-year 2026 net revenue guidance was raised to $314–$320 million, Adjusted EBITDA guidance set at $64–$68 million, and net capital expenditures are now expected at 8.5%–10.0% of net revenue.
Viemed Healthcare, Inc. reported the results of its Annual General and Special Meeting. Shareholders approved a second amendment to the 2024 Long Term Incentive Plan, increasing the maximum number of common shares reserved for issuance under current and prior equity plans to 7,696,717, including up to 1,000,000 incentive stock options. All seven director nominees were elected, each receiving at least 79.76% support, with broker non-votes of 5,139,303 on the election item. Shareholders also approved the appointment of Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2026. The equity plan amendment and executive compensation received strong backing, with 88.85% and 93.21% of votes cast in favor, respectively, on the compensation-related resolutions.
Viemed Healthcare highlights strong growth and guidance in its June 2026 investor presentation. Net revenue reached $270 million in 2025, up 28% year over year, with Adjusted EBITDA of $61 million and free cash flow of $28 million, all with no net debt. The company reports a 26% compounded annual revenue growth rate since listing, serves over 183,000 patients across all 50 states, and has diversified beyond ventilation into sleep, oxygen, airway clearance, women’s health and staffing. For 2026, Viemed guides to net revenue of $312–$320 million and Adjusted EBITDA of $65–$69 million, while maintaining net capex at 9–10.5% of revenue and trailing twelve-month free cash flow of about $36 million. Management is also executing a new share repurchase program of up to 5% of shares outstanding, supported by cash generation and $46 million of credit facility availability.
Viemed Healthcare reported strong first quarter 2026 growth while narrowing and raising its full-year outlook. Net revenue for the quarter ended March 31, 2026 was $75.4 million, up 28% from the prior-year quarter. Net income attributable to Viemed was $2.6 million, or $0.06 per diluted share, and Adjusted EBITDA rose 12% to $14.3 million, despite a non-recurring gain in the prior year.
The company generated $8.1 million of operating cash flow and $2.6 million of free cash flow in the quarter, repurchased 150,000 shares for $1.4 million, and reduced term debt by $3.2 million. Management now expects 2026 net revenue of $312–$320 million, Adjusted EBITDA of $65–$69 million, and lower net capital intensity of 9%–10.5% of net revenue.
Viemed Healthcare used a new investor presentation to highlight strong 2025 performance and 2026 guidance. For 2025, the company reported $270M in net revenue, $61M Adjusted EBITDA, $28M free cash flow, nine straight years of positive net income, and effectively $0M net debt.
The business is increasingly diversified, with sleep representing 21% of Q4 2025 net revenue and showing 62% year-over-year growth in PAP therapy patients and 49% growth in sleep resupply patients. Management is guiding 2026 net revenue to $310M–$320M and Adjusted EBITDA to $65M–$69M, with net capex of 10%–11.5% of net revenue.
The company emphasizes a capital-light, home-based care model, expanding from complex ventilation into sleep, oxygen, airway clearance, women’s health and staffing. With more than 172,000 patients across all 50 states, $46M of credit facility availability, and a newly authorized share repurchase program covering up to 5% of shares outstanding, Viemed presents itself as a growth platform supported by regulatory stability and a strong balance sheet.
Viemed Healthcare reported record 2025 results with net revenue of $270.3 million, up 21% from 2024, driven by organic growth and its Lehan's Medical Equipment acquisition. Net income attributable to Viemed rose 33% to $14.9 million, and Adjusted EBITDA reached a record $61.4 million.
The company generated strong free cash flow of $28.1 million for 2025, up sharply from $11.6 million, while ventilator, PAP therapy, and sleep resupply patient counts all increased. For 2026, Viemed guides net revenue to $310–$320 million and Adjusted EBITDA to $65–$69 million. The board also approved a new share repurchase program for up to 1,930,131 common shares, about 5% of shares outstanding, effective through March 2027.
Viemed Healthcare, Inc. reported a Third Amendment to its Credit Agreement with Regions Bank and other lenders. The change extends the Borrower’s delayed draw term loan commitment expiration date to November 29, 2026, from November 29, 2025, with additional technical amendments. This keeps the facility available for an extra year under the amended terms.
The company also made an Investor Deck Presentation available and may use it in discussions with investors and analysts. As indicated, this presentation and related Item 7.01 information are furnished, not filed, under the Exchange Act.
Viemed Healthcare (VMD) furnished an 8-K to announce its financial results for the three and nine months ended September 30, 2025. The company provided a press release and a Financial Supplement as exhibits.
The materials are furnished under Item 2.02 and, under General Instruction B.2, are not deemed filed or subject to Section 18 liabilities. Exhibits include the press release (99.1) and Financial Supplement (99.2), both dated November 5, 2025.
Viemed Healthcare, Inc. announced on September 23, 2025 that it has completed its previously authorized share repurchase program. The company repurchased a total of 1,976,441 common shares for an aggregate purchase price of approximately $13.2 million, before applicable taxes. The announcement was issued via a press release furnished as Exhibit 99.1 to the Current Report and is incorporated by reference. The filing notes the press release and related Item 7.01 information are furnished and not "filed" for purposes of Section 18 of the Exchange Act.
Viemed Healthcare, Inc. (VMD) filed an 8-K to announce the closing of its acquisition of Lehan’s Medical Equipment, a privately held home medical equipment provider based in DeKalb, Illinois. The transaction consists of a $26 million base purchase price, subject to customary adjustments, plus an estimated $2.2 million contingent consideration.
The company stated that it will update its full-year 2025 guidance to reflect Lehan’s expected contribution when it reports Q2 2025 earnings (period ended June 30, 2025). No immediate changes to guidance or pro-forma financials were included in this filing; the related press release is furnished as Exhibit 99.1 and deemed “furnished,” not “filed,” under the Exchange Act.
For investors, the filing signals completion of a strategic bolt-on acquisition that expands VMD’s geographic reach into Illinois and broadens its home medical equipment offerings. The cash outlay and contingent payments may affect near-term liquidity, while future revenue impact will be clarified with the forthcoming guidance update.